What Letairis Treats: Main Uses and Benefits

Letairis (ambrisentan) is generally used for the long-term management of Pulmonary Arterial Hypertension (PAH), a condition involving high blood pressure in the arteries of the lungs. This treatment is applied in conditions involving episodic or fluctuating manifestations, such as WHO Group 1 PAH, including idiopathic PAH (of unknown cause) or forms associated with connective tissue diseases.

The medicine is applied to help reduce high resistance within the lung arteries. This reduction helps to support the right side of the heart, which may assist with maintaining a sense of stability when symptoms are more noticeable. The medication is generally applied to help manage the symptom clusters of shortness of breath and fatigue that interfere with daily functioning.

---

Improving Physical Functional Ability

The medication is commonly used when symptoms create noticeable physiological strain, often corresponding to functional limitations like WHO Functional Class II or III. The medication may assist with improving exercise capacity and supports an increased tolerance for daily activities, helping patients cope more steadily with symptom fluctuations. This medicine is generally relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load. Its use, often in combination therapy, is generally relevant when supportive symptom management is appropriate, and it may assist with maintaining functional stability during phases when symptoms become more noticeable. This long-term approach supports the sustained management of this condition.

Quick Fact: Relief for Functional Symptoms
Primary Indication: Pulmonary Arterial Hypertension (PAH), WHO Group 1.
Symptom Domain: Shortness of breath and fatigue related to physical effort.
Key Benefit: Supports sustained functional stability and improves exercise capacity.
Context of Use: Chronic, long-term management in symptomatic patients (Class II/III).

Who Can and Cannot Use Letairis?

Letairis (ambrisentan) is officially indicated for adult patients with Pulmonary Arterial Hypertension (PAH), specifically those with WHO Functional Class II or III symptoms. Regulatory documents define eligibility through strict exclusionary rules and restrictions based on population status and comorbidities.

Absolute Contraindications

The medicine is absolutely contraindicated for pregnant females or females who may become pregnant, due to significant risk of fetal harm. It is also prohibited for patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and those with severe hepatic impairment or markedly elevated liver enzymes (ALT/AST >3x ULN).

Restrictions and Limitations

Use is subject to significant restrictions for all females, who must participate in a mandatory risk management program (REMS or equivalent) requiring regular pregnancy tests and the use of reliable contraception. Regarding age, safety and effectiveness have not been established in the pediatric population.

Condition-Based Rules

Letairis is not recommended in patients with moderate hepatic impairment or clinically significant anemia, and use should proceed with caution in cases of severe renal impairment. Regulatory guidance advises that breastfeeding is not recommended during treatment.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of ambrisentan through pharmacokinetic and pharmacodynamic mechanisms, leading to specific restrictions. Ambrisentan is a substrate for the drug transport proteins OATP and P-glycoprotein (P-gp). It is not an inhibitor or inducer of major CYP enzymes (CYP3A, CYP2C19) at clinically relevant concentrations, meaning it generally does not alter the metabolism of many co-administered drugs.

Official Interaction Statements

Interaction Classification	Interacting Substance	Officially Documented Outcome
Exposure Modification (Pharmacokinetic)	Cyclosporine	Co-administration results in an approximate 2-fold increase in ambrisentan exposure (AUC).
Formal Contraindication (Pharmacodynamic)	Sparsentan	Co-administration is contraindicated due to increased pharmacodynamic risks documented by some regulators.
Pharmacodynamic Risk	Tadalafil	Officially documented increased incidence of peripheral edema and anemia compared to ambrisentan taken alone.
Food Rule	Food	May be administered with or without food.

Interaction-Based Restrictions

When co-administered with Cyclosporine, the ambrisentan dose must be limited to 5 mg once daily to mitigate the risk associated with the increased exposure. Although Rifampin causes a transient increase in exposure acutely, this effect is not considered clinically relevant over the long term. No mandatory time separation rules are documented for co-administration with other medicines.

Selective Antagonism of the ET A Receptor

The mechanism of action centers on acting as a highly selective antagonist that blocks the Endothelin Type A receptor ( ET A), the key molecular target for the potent vasoconstrictor, ET-1 (Endothelin-1). By occupying this receptor, the drug suppresses the signaling that drives smooth muscle contraction and subsequent cell growth signals in the vessel walls.

---

Modulating Vascular Tone and Resistance

This targeted molecular blockade initiates a mechanistic cascade that directly modulates both the short-term function (tone) and long-term structure (remodeling) of the blood vessels. By interrupting the ET A-mediated contractile signal, the drug promotes sustained vasodilation and exerts an antiproliferative effect. This physiological change lowers the impedance to blood flow, resulting in a reduction in Pulmonary Vascular Resistance (PVR).

---

Functional ET B Receptor Sparing

The drug's high selectivity for the ET A subtype means it minimally interacts with the ET B receptor, a characteristic that results in the maintenance of ET B receptor-mediated functions. The ET B receptor is associated with two important processes: the clearance of ET-1 from the bloodstream and the release of other protective vasodilators like nitric oxide ( NO). This selective mechanism focuses on the pathological vasoconstriction pathway while permitting the function of these naturally regulated processes.

General Administration and Dosing

Letairis (ambrisentan) is administered as an oral film-coated tablet and is intended for chronic, long-term management. The medicine is taken once daily, establishing a consistent dosing schedule. Administration is flexible with respect to meals, as the tablet may be consumed with or without food.

Dosing Parameter	Guideline
Starting Dose	5 mg once daily
Maintenance Dose	10 mg once daily
Titration Interval	Minimum 4 weeks on starting dose
Maximum Dose	10 mg once daily

A starting dose of 5 mg once daily is established for initial treatment. If the 5 mg dose is well-tolerated, the daily dose may be increased to the maximum recommended dose of 10 mg, a change generally considered after a minimum treatment period of 4 weeks. The tablets must be swallowed whole and should not be split, crushed, or chewed.

Procedural Constraints

For specific patient populations, particular usage instructions are mandated. The dose must be limited to 5 mg once daily when the medicine is co-administered with cyclosporine. Furthermore, female patients of reproductive potential are required to participate in a restricted distribution program that includes mandatory monthly monitoring. If a dose is missed, the patient should simply resume the treatment schedule by taking the next dose at the usual time.

Research Evidence / Overview of Studies for Letairis

This section describes the types of research that have been conducted on ambrisentan, what the studies monitored, and where the evidence remains limited. It does not provide medical advice or instructions on how the medicine should be used.

---

Evidence for Use as a Single Initial Therapy (Monotherapy) and Combination Therapy

Research included two Phase III short-term, randomized, placebo-controlled trials examining ambrisentan as a single initial therapy for Pulmonary Arterial Hypertension (PAH). These studies explored how functional capacity is measured in adults with moderate limitations. In these controlled settings, research described patterns in measurements of functional capacity and monitored the time to clinical worsening.

Research also explored initial combination therapy when ambrisentan was observed in one long-term, event-driven, active-controlled trial alongside another specific PAH drug. This research monitored responses over defined time intervals, primarily examining the time to clinical failure, a specific composite primary endpoint. The findings indicated patterns related to the occurrence of these events in treatment-naïve adult patients.

---

Evidence in Specific Patient Groups (Special Populations)

For pediatric patients (children aged 8 to less than 18), evidence is limited and comes primarily from a small, 6-month randomized, open-label trial followed by a long-term open-label extension study. Research for older adults and patients with PAH associated with connective tissue diseases exists in the form of subgroup analyses within the main adult clinical trials. These subgroup findings are uncertain and must be viewed with caution.

---

Long-Term Studies and Follow-up

Since the main controlled trials were only short-term, long-term outcomes were observed in separate, open-label extension studies, tracking outcomes related to functional status and activity level. Because these extension studies were not placebo-controlled, limitations are introduced. Evidence quality varies across studies, and certainty remains low for outcomes based solely on non-controlled long-term data.

---

Evidence Gaps and Areas of Uncertainty

Research is ongoing, but long-term effects are not fully established based on highly controlled evidence. The initial follow-up durations were limited in the most rigorous trials, which is a key research limitation frame for a lifelong illness. Additionally, comparative evidence is lacking regarding ambrisentan's performance against certain other endothelin receptor antagonists. Research provides context but not individual predictions.

How to Store and Dispose of Letairis (Ambrisentan)

Official Storage Conditions

Letairis tablets must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The medication must remain in its original package or container as dispensed. For child safety, the product must be kept out of the reach of children.

Handling and Disposal Rules

Ambrisentan is classified as a hazardous drug due to reproductive concerns, and specific handling procedures, such as the use of gloves, are recommended when handling the tablets. The official disposal instructions prohibit throwing away unused or expired medicine via wastewater or household waste. Instead, the product must be returned to a pharmacist or a designated collection point for proper environmental protection and controlled waste management.